LALuigi Atripaldi

Luigi Atripaldi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luigi Atripaldi has a total of 171 co-authors. Here are the top co-authors by number of shared publications:

  • Alessandro Perrella

    Emerging Infectious Disease and High Contagiousness Unit, P.O. D. Cotugno-AORN Ospedali dei Colli, 80131 Naples, Italy

    15 shared publications
  • Costanza Sbreglia

    VII Dpt Infectious Disease and Immunology; Hospital D.Cotugno; Naples Italy

    9 shared publications
  • Oreste Perrella

    VII Dpt Infectious Disease and Immunology; Hospital D.Cotugno; Naples Italy

    9 shared publications
  • O. Perrella

    Department of Infectious Disease and Immunology, Hospital D.Cotugno Naples, Naples, Italy

    5 shared publications
  • C. Sbreglia

    Department of Infectious Disease and Immunology, Hospital D.Cotugno Naples, Naples, Italy

    4 shared publications
  • Stella Grattacaso

    Department of Infectious Disease and Immunology, Hospital D. Cotugno, Naples, Italy

    4 shared publications

Latest Publications

  • Open Access

    Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up

    by Annachiara Coppola, Carlo Buonerba, Davide Cardinale, Gabriella Lo Conte, Donato Sansone, Giuseppe Rofrano, Sabato De Vita, Maria Morgante, Maria Triassi, Luigi Atripaldi, et al.

    As of November 17, 2021, SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2), the causative agent of COVID-19 (COronaVIrus Disease 19), has infected ~250 million people worldwide, causing around five million deaths. Titers of anti-SARS-CoV-2 neutralizing antibodies were relatively stable for at least 9 months in a population-based study conducted in Wuhan, China, both in symptomatic and in asymptomatic individuals. In the mass screening campaign conducted in the town of Ariano Irpino (Avellino, Italy) in May, 2020, 5.7% (95% CI: 5.3-6-1) of the 13,444 asymptomatic citizens screened were positive for anti-nucleocapsid antibodies against SARS-CoV-2. Among these, 422 citizens were re-tested for anti SARS-CoV-2 antibodies in January, 2021 and/or in April, 2021 and enrolled in this longitudinal observational study. Median (interquartile range) age of the study cohort was 46 years (29–59), with 47 (11.1%) participants of minor age, while 217 (51.4%) participants were females. There was no evidence of re-infection in any of the subjects included. Presence of anti-nuclear antibodies antibodies (Elecysis, Roche) was reported in 95.7 and 93.7% of evaluable participants in January and April, 2021. Multiple logistic regression analysis used to explore associations between age, sex and seroprevalence showed that adults vs. minors had significantly lower odds of having anti-S1 antibodies (Biorad) both in January, 2021 and in April, 2021. Our findings showed that antibodies remained detectable at least 11.5 months after infection in >90% of never symptomatic cases. Further investigation is required to establish duration of immunity against SARS-CoV-2.


  • Open Access

    Long-chain polyphosphates impair SARS-CoV-2 infection and replication

    by Veronica Ferrucci, Dae-Young Kong, Fatemeh Asadzadeh, Laura Marrone, Angelo Boccia, Roberto Siciliano, Giuseppina Criscuolo, Camilla Anastasio, Fabrizio Quarantelli, Marika Comegna, et al.

    Inorganic polyphosphates (polyPs) are linear polymers composed of repeated phosphate (PO43−) units linked together by multiple high-energy phosphoanhydride bonds. In addition to being a source of energy, polyPs have cytoprotective and antiviral activities. Here, we investigated the antiviral activities of long-chain polyPs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In molecular docking analyses, polyPs interacted with several conserved amino acid residues in angiotensin-converting enzyme 2 (ACE2), the host receptor that facilitates virus entry, and in viral RNA-dependent RNA polymerase (RdRp). ELISA and limited proteolysis assays using nano– LC-MS/MS mapped polyP120 binding to ACE2, and site-directed mutagenesis confirmed interactions between ACE2 and SARS-CoV-2 RdRp and identified the specific amino acid residues involved. PolyP120 enhanced the proteasomal degradation of both ACE2 and RdRp, thus impairing replication of the British B.1.1.7 SARS-CoV-2 variant. We thus tested polyPs for functional interactions with the virus in SARS-CoV-2–infected Vero E6 and Caco2 cells and in primary human nasal epithelial cells. Delivery of a nebulized form of polyP120 reduced the amounts of viral positive-sense genomic and subgenomic RNAs, of RNA transcripts encoding proinflammatory cytokines, and of viral structural proteins, thereby presenting SARS-CoV-2 infection in cells in vitro.


  • SERUM cardiac‐specific biomarkers and atrial fibrillation in myotonic dystrophy type I

    by Vincenzo Russo, Anna Rago, Luigi Atripaldi, Silvia Leonardi, Andrea Antonio Papa, Luisa Politano, Paolo Golino, Tatjana S. Potpara, Gerardo Nigro

    Introduction: The aim of the present study was to evaluate the role of high‐sensitivity cardiac troponin I, N terminal pro‐B‐type natriuretic peptide (NT‐proBNP), creatine kinase‐MB mass concentration (CK‐MB mass) and copeptin (CP) in predicting incident atrial fibrillation (AF) in myotonic dystrophy type 1 (DM1) patients.Materials and methods: The study enrolled 60 consecutive DM1 patients (age 50.3 ± 7.3 years, 34 male) who underwent pacemaker (PM) implantation for cardiac rhythm abnormalities and 60 PM recipients whose age and sex matched served as control group. All DM1 patients underwent a 12‐lead electrocardiogram, 2D color Doppler echocardiogram, biomarkers measurements and device interrogation at implantation, 1 month after and every 6 months thereafter for a minimum of 2‐year follow‐up.Results: The study population was divided into two groups according to the presence of AF (AF group vs non‐AF group). The AF group was older (47.3 ± 8 vs 38.6 ± 7 years, P = .03) and showed higher serum levels of NT‐proBNP (151 ± 38.4 vs 107.3 ± 24.2 pg/mL, P < .001) and CP (18.9 ± 4.5 vs 7 ± 2.3 P < .001) than non‐AF Group. NT‐proBNP (P < .001) and CP (P < .001) were found to be an independent predictor of AF. Based on the receiver‐operating characteristics curve analysis, the cut‐off value for NT‐proBNP that best predicted AF event in DM1 patients was 123 pg/ml (sensitivity of 83.3% and specificity of 86.5%); the cut‐off value for CP that best predicted AF event in DM1 patients was 9 pmol/L (sensitivity of 89% and specificity of 87%).Conclusion: NT‐proBNP and CP represent two independent predictors of AF onset in DM1 population with conduction disturbances underwent PM implantation.


    • 1 January 2019
      • Vol. 42  (1) , 49-51

    Neonatal pertussis diagnosis: low procalcitonin level and high lymphocyte count are able to discriminate pertussis from bacterial and viral infections

    by Carlo Tascini, Novella Carannante, Giuseppe Sodano, Claudia Tiberio, Luigi Atripaldi, Giovanni Di Caprio, Emanuela Sozio, Francesco Sbrana, Andrea Ripoli, Camilla Menchini, et al.

    Pertussis is quite frequent and severe among infants; therefore, rapid diagnosis and timely targeted therapy are essential. Although a molecular test for etiological diagnosis is now available, it may not be available everywhere, and therefore adjunctive diagnostic tests are still useful for presumptive diagnosis. We describe the use of procalcitonin (PCT) and lymphocyte count to discriminate among pertussis, bacterial and viral infections. Fourteen infants per group were studied. The decision tree, built considering all available variables, showed a major role of PCT in predicting the different groups. A PCT value equal to or greater than 0.75 ng/ml selected for bacterial infections. A PCT value lower than 0.75 ng/ml and a lymphocyte count equal to or greater than 10,400/mm(3) selected the subjects with pertussis, while a lymphocyte count lower than 10,400/mm(3) selected for viral etiology. PCT should be used in the diagnosis of infants suspected of having pertussis.


  • Utility of peripheral blood smear in rapid diagnosis of Pertussis

    by Tiziana Di Matola, Ciro Miele, Maurizio Coppola, Maurizio Fumi, Ylenia Pancione, Silvia Sale, Luigi Atripaldi, Vincenzo Rocco


  • Direct antiviral treatment of chronic hepatitis C in heart transplant recipients

    by Martina Vitrone, Roberto Andini, Irene Mattucci, Ciro Maiello, Luigi Atripaldi, Emanuele Durante‐Mangoni, Rosa Zampino

    Direct‐acting antiviral agents (DAAs) are a safe and effective treatment for chronic hepatitis C (CHC). This may be particularly valuable for patients with severe comorbidities or baseline conditions, including non‐liver solid organ transplant. We report cases of two heart transplant recipients with CHC treated with DAAs (sofosbuvir and daclatasvir) achieving sustained virological response. Treatment was well tolerated and no relevant side effects were observed. The drug‐drug interactions and graft function were carefully monitored.


  • Open Access

    Assessment of Pharmacogenomic Panel Assay for Prediction of Taxane Toxicities: Preliminary Results

    by Raffaele Di Francia, Luigi Atripaldi, Salvo Di Martino, Carla Fierro, Tommaso Muto, Anna Crispo, Sabrina Rossetti, Gaetano Facchini, Massimiliano Berretta

    Backbone: Paclitaxel and docetaxel are the primary taxane anticancer drugs regularly used to treat, breast, gastric, ovarian, head/neck, lung, and genitourinary neoplasm. Suspension of taxane treatments compromising patient benefits is more frequently caused by peripheral neuropathy and allergy, than to tumor progression. Several strategies for preventing toxicity have been investigated so far. Recently, findings on the genetic variants associated with toxicity and resistance to taxane-based chemotherapy have been reported. Methods: An extensive panel of five polymorphisms on four candidate genes (ABCB1, CYP2C8*3, CYP3A4*1B, XRCC3), previously validated as significant markers related to paclitaxel and Docetaxel toxicity, are analyzed and discussed. We genotyped 76 cancer patients, and 35 of them received paclitaxel or docetaxel-based therapy. What is more, an early outline evaluation of the genotyping costs and benefit was assessed. Results: Out of 35 patients treated with a taxane, six (17.1%) had adverse neuropathy events. Pharmacogenomics analysis showed no correlation between candidate gene polymorphisms and toxicity, except for the XRCC3 AG+GG allele [OR 2.61 (95% CI: 0.91–7.61)] which showed a weak significant trend of risk of neurotoxicities vs. the AG allele [OR 1.52 (95% CI: 0.51–4.91)] P = 0.03. Summary: Based on our experimental results and data from the literature, we propose a useful and low-cost genotyping panel assay for the prevention of toxicity in patients undergoing taxane-based therapy. With the individual pharmacogenomics profile, clinicians will have additional information to plan the better treatment for their patients to minimize toxicity and maximize benefits, including determining cost-effectiveness for national healthcare sustainability.


  • Open Access

    Effects of defibrillation shock in patients implanted with a subcutaneous defibrillator: a biomarker study

    by Antonio D’onofrio, Vincenzo Russo, Valter Bianchi, Ciro Cavallaro, Silvia Leonardi, Stefano De Vivo, Filippo Vecchione, Anna Rago, Ernesto Ammendola, Vincenzo Tavoletta, et al.

    Implantable cardioverter defibrillator (ICD) shocks are associated with a subsequent increased risk of death, and an elevation of cardiac enzymes has been measured after defibrillation testing (DFT). In an experimental swine study, subcutaneous ICD (S-ICD) shocks caused less myocardial damage than traditional ICD shocks. The aim of our study was to investigate the association between S-ICD shock and acute cardiac damage in humans, as evaluated by means of sensitive and highly specific circulating biomarkers. We calculated the variation in the serum levels of high-sensitivity cardiac troponin I (hs-CTnI) and creatine kinase-MB mass concentration (CK-MB mass), measured before and after an S-ICD shock delivered during intraoperative DFT. We also measured the degree of haemodynamic stress, as the variation in the serum levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and copeptin (CP), after the S-ICD shock. We analysed 30 consecutive patients who received an S-ICD and who underwent DFT by means of a single 65 J shock. The levels of biomarkers did not change from baseline to 1 h post-shock, i.e. hs-CTnI (from 0.029 ± 0.005 ng/mL to 0.030 ± 0.005 ng/mL, P = 0.079) and CK-MB mass (from 1.37 ± 0.17 ng/mL to 1.41 ± 0.18, P = 0.080) and remained stable 6 and 24 h after DFT. The plasma NT-proBNP did not change, whereas CP levels were significantly higher at 1 h post-shock evaluation. However, 6 h after DFT, the levels had returned to the baseline and remained stable at 24 h. The S-ICD shock did not seem to cause myocardial injuries. Although CP levels temporarily rose after DFT, they returned to basal levels within 6 h, which suggests that DFT does not have long-term prognostic implications. ICD shocks are associated with a subsequent increased risk of death, and an elevation of cardiac enzymes has been measured after DFT. We showed that serum levels of biomarkers of myocardial damage did not increase after high-energy DFT in patients who had undergone S-ICD device implantation. This suggests that S-ICD shock does not have long-term prognostic implications.


  • Open Access

    Drug–Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antiblastic Chemotherapy in Cancer Patients with HIV Infection

    by Massimiliano Berretta, Michele Caraglia, Ferdinando Martellotta, Silvia Zappavigna, Angela Lombardi, Carla Fierro, Luigi Atripaldi, Tommaso Muto, Daniela Valente, Paolo De Paoli, et al.

    The introduction of Highly Active Antiretroviral Therapy (HAART) into clinical practice has 27 dramatically changed the natural approach of HIV-related cancers. Several studies have shown that 28 intensive antiblastic chemotherapy (AC) is feasible in HIV-infected patients with cancer, and that the 29 outcome is similar to that of HIV-negative patients receiving the same AC regimens. However, the 30 concomitant use of HAART and AC can result in drug accumulation or possible toxicity with 31 consequent decreased efficacy of one or both classes of drugs. In fact, many AC agents are 32 preferentially metabolized by CYP450 and drug-drug interactions (DDIs) with HAART are common. 33 Therefore, it is important that HIV patients with cancer in HAART receiving AC treatment at the 34 same time receive an individualized cancer management plan based on their liver and renal 35 functions, their level of bone marrow suppression, their mitochondrial dysfunction and their 36 genotype profile. The rationale of this review is to summarize the existing data on the impact of 37 HAART on the clinical management of cancer patients with HIV/AIDS and DDIs between 38 antiretrovirals and AC. In addition, in order to maximize the efficacy of antiblastic therapy and 39 minimize the risk of drug-drug interaction, a useful list of pharmacogenomic markers is provided.


  • Open Access

    CD4+/CD25+ T cells suppress autologous CD4+/CD25- lymphocytes and secrete granzyme B during acute and chronic hepatitis C

    by Alessandro Perrella, Anna D'Antonio, Costanza Sbreglia, Paolo Sorrentino, Paolo Conca, Luigi Atripaldi, Pio Conti, Oreste Perrella